AHA Coding Clinic® for HCPCS - 2017 Quarter 1; Ask the Editor
Xen glaucoma treatment
The Food and Drug Administration (FDA) approved the Xen Glaucoma Treatment System in November 2016. The system is used to treat intraocular pressure (IOP) in patients with refractory glaucoma or in patients with primary open angle glaucoma and pseudoexfoliative or pigmentary glaucoma with open angles that are unresponsive to maximum tolerated medical therapy. The system consists of an implantable gel stent and an injector. Is there a Level II HCPCS codes that describes the Xen Glaucoma Treatment System? ...
Subscribe or sign in to view the full article.
Article Overview
This article covers the Xen Glaucoma Treatment System and its use in glaucoma care, including the FDA approval context and a question-and-answer discussion of how the device is represented in HCPCS Level II. It is aimed at coders, billers, and healthcare professionals who need to identify the relevant reporting framework for an ocular implant used in glaucoma treatment.
Why This Topic Matters
Accurate identification of the applicable HCPCS Level II code helps support consistent reporting of a glaucoma-related ocular implant device and reduces confusion about how the system is categorized for administrative purposes.
What You Will Learn
- The clinical and administrative context for the Xen Glaucoma Treatment System
- How the article frames the relevant HCPCS Level II reporting issue
- What broad device category the article discusses in relation to glaucoma treatment
- The role of FDA approval context in the article
Who Should Read This
- Medical coders
- Medical billers
- Ophthalmology practices
- Revenue cycle staff
- Healthcare administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com